Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Clinical trial NCT06236438 · RECRUITING
Trial details
- NCT number
- NCT06236438
- Sponsor
- AbbVie
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-10
- Primary completion
- 2031-10-01
- Enrollment
- 840
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.